Onkologie. 2022:16(5):250-253 | DOI: 10.36290/xon.2022.047
Hypofrakcinovaná protonová radioterapie karcinomu prostaty - 6letá data
- Proton Therapy Center Czech, s. r. o., Praha
Cíl práce: Cílem práce je analýza 6letého přežití bez biochemického relapsu (bDFS) a profilu pozdní toxicity u nemocných s karcinomem prostaty léčených ultrahypofrakcionovanou protonovou radioterapií.
Klíčová slova: karcinom prostaty, protonová radioterapie, pencil beam scanning, ultrahypofrakcionace.
Hypofractionated proton radiotherapy for prostate cancer: six-year data
Objective: The aim of the paper is an analysis of the six-year biochemical disease-free survival (bDFS) rate and of the late toxicity profile in patients with prostate cancer treated with ultra-hypofractionated proton radiotherapy.
Material and methods: Between March 2013 and February 2016, a total of 275 patients were treated with ultra-hypofractionated proton radiotherapy (36.25 GyE/5 fractions). The median follow-up time is 69 months. There were 118 (42.9%) patients with low and 157 (57.1%) patients with intermediate-risk prostate cancer. Fifty (18.2%) patients received neoadjuvant hormone therapy, while none had adjuvant hormone therapy.
Results: The estimated six-year bDFS rate was 97.1% (SD 1.7%) and 89.9% (SD 3.0%) for low- and intermediate-risk prostate cancer, respectively. Cumulative late toxicity (CTCAE-v.4) grade ≥ 2 was found for gastrointestinal toxicity (GI) in 17 (6.2%) patients and for genitourinary toxicity (GU) in 11 (4.0%) patients. The estimated cumulative GI toxicity grade ≥ 2 at six years was 6.3% GI and 4.1% for GU toxicity. PSA relapse was observed in 16 (5.8%) patients. During the course of follow-up, 14 (5.1%) patients died.
Conclusion: Ultra-hypofractionated proton radiotherapy with the PBS technique is highly effective in treating low- and intermediate-risk prostate cancer with a favourable profile of late gastrointestinal and genitourinary toxicity.
Keywords: prostate carcinoma, proton radiotherapy, pencil beam scanning, ultra hypofractionation.
Přijato: 29. září 2022; Zveřejněno: 29. září 2022
Reference
- King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiotherapy and Oncology. 2013;109:217-221.
Přejít k původnímu zdroji... 
Přejít na PubMed... - Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined Prostate Cancer, a 7-Year Study. Front Oncol. 2014;4:301. Přejít k původnímu zdroji... Přejít na PubMed...
- Kishan AU, King CR. Stereotactic body radiotherapy for low and intermediate-risk prostate cancer. Seminars in Radiation Oncology. 2017;27(3):268-278. doi: 10.1016/j.semradonc.2017.02.006. Přejít k původnímu zdroji... Přejít na PubMed...
- Bryant C, Smith TL, Henderson RH, et al. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):422-434. doi:10.1016/j.ijrobp.2016.02.038. Přejít k původnímu zdroji... Přejít na PubMed...
- Takagi M, Demizu Y, Terashima K, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017;6(10):2234-2243. doi: 10.1002/cam4.1159. Přejít k původnímu zdroji... Přejít na PubMed...
- Iwata H, Ishikawa H, Takagi M. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018;7(3):677-689. doi: 10.1002/cam4.1350. Epub 2018 Feb 14. Přejít k původnímu zdroji... Přejít na PubMed...